Control of gluconeogenesis by metformin: does redox trump energy charge?

Article Details

Citation

Copy to clipboard

Baur JA, Birnbaum MJ

Control of gluconeogenesis by metformin: does redox trump energy charge?

Cell Metab. 2014 Aug 5;20(2):197-9. doi: 10.1016/j.cmet.2014.07.013.

PubMed ID

25100057 [ View in PubMed

]

Abstract

Metformin is the most widely prescribed drug to lower glucose in type II diabetics, yet its mechanism of action remains controversial. A new study reveals that metformin inhibits mitochondrial glycerol-3-phosphate dehydrogenase, triggering reduction of the cytosolic NADH/NAD(+) pool and impaired utilization of redox-dependent substrates for gluconeogenesis (Madiraju et al., 2014).

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Metformin	Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic	Protein	Humans	Unknown	Inhibitor	Details